Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database
Daniel Taussky1,2, Felix Preisser3,4, Pierre I. Karakiewicz1,5, Derya Tilki3,4, Carole Lambert1,2, Jean-Paul Bahary1,2, Guila Delouya1,2, Robert Wistaff2,6, Mikhael Laskine2,6, Paul Van Nguyen2,6, Madeleine Durand2,6, Fred Saad5
Canadian Journal of Urology, Vol.25, No.5, pp. 9509-9515, 2018
Abstract Introduction: Conflicting data exists on the influence of metformin on prostate cancer. We investigated the importance of metformin in patients treated with radiotherapy or brachytherapy.
Materials and methods: All patients from a large institutionalized database, treated for primary localized prostate cancer with either brachytherapy or external-beam radiotherapy ± androgen deprivation therapy were identified. Groups were compared by Kaplan–Meier analyses and Cox regression models. Multivariate analysis was adjusted for CAPRA-Score, type of treatment, and age.
Results: A total of 2441 patients with complete data was identified. Among them, 382 patients (16% of total) were diabetic. Two hundred eighty-one of… More >